Clinical Practice GuidelineRadiation Therapy for Brain Metastases: An ASTRO Clinical Practice Guideline
Section snippets
Preamble
As the leading organization in radiation oncology, the American Society for Radiation Oncology (ASTRO) is dedicated to improving quality of care and patient outcomes. A cornerstone of this goal is the development and dissemination of clinical practice guidelines based on systematic methods to evaluate and classify evidence, combined with a focus on patient-centric care and shared decision making. ASTRO develops and publishes guidelines without commercial support, and members volunteer their
Task force composition
The task force consisted of a multidisciplinary team of radiation, medical, and neurosurgical oncologists; a radiation oncology resident; a medical physicist; and a patient representative. This guideline was developed in collaboration with the American Association of Neurological Surgeons/Congress of Neurological Surgeons, ASCO, and SNO, who provided representatives and peer reviewers.
Document review and approval
The guideline was reviewed by 20 official peer reviewers (Appendix E1, Supplementary Materials) and revised
KQ 1: Indications for SRS alone for patients with intact brain metastases (Table 3)
See evidence tables in Appendix E3 (Supplementary Materials) for the data supporting the recommendations for KQ1.
What are the indications for SRS alone for patients with intact brain metastases?
Progression of intracranial metastases can lead to neurologic morbidity and death. WBRT remained the standard of care for decades, but the development of SRS allowed treatment of limited brain metastases alone, often in a single fraction, while largely sparing surrounding brain. Initially, neither the risks of omitting treatment of grossly uninvolved brain nor the exact benefits of
Conclusions and Future Directions
In the decade since the previous ASTRO brain metastasis guideline,3 there has been a tremendous evolution in the management of this patient population. Novel RT techniques such as HA-WBRT have been developed that improve the therapeutic ratio, SRS has a more predominant role, and newer systemic agents have demonstrated unprecedented CNS activity. Treatment and management decisions (Figs. 1 and 2) depend on multiple factors (eg, number of brain metastases, brain metastasis size, and performance
Acknowledgments
We are grateful to the AHRQ evidence-based practice center that performed the systematic review of the evidence, and to the Patient-Centered Outcomes Research Institute for funding the systematic review. The task force also appreciates the data abstraction assistance provided by Madeera Kathpal, DO, and Amber Retzlaff, MD. The task force thanks the peer reviewers for their comments and time spent reviewing the guideline. See Appendix E1 in Supplementary Materials for their names and disclosures.
References (106)
- et al.
Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): An American Society for Radiation Oncology evidence-based guideline
Prac Radiat Oncol
(2012) - et al.
Radiation therapy for brain metastases: A systematic review
Pract Radiat Oncol
(2021) - et al.
Radiation therapy for small cell lung cancer: An ASTRO clinical practice guideline
Pract Radiat Oncol
(2020) - et al.
Single- and multifraction stereotactic radiosurgery dose/volume tolerances of the brain
Int J Radiat Oncol Biol Phys
(2021) - et al.
Stereotactic radiosurgery with or without whole-brain radiation therapy for limited brain metastases: A secondary analysis of the North Central Cancer Treatment Group N0574 (Alliance) randomized controlled trial
Int J Radiat Oncol Biol Phys
(2017) - et al.
Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: A randomised controlled trial
Lancet Oncol
(2009) - et al.
Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): A multi-institutional prospective observational study
Lancet Oncol
(2014) - et al.
Initial SRS for patients with 5 to 15 brain metastases: Results of a multi-institutional experience
Int J Radiat Oncol Biol Phys
(2019) - et al.
A cohort study of stereotactic radiosurgery results for patients with 5 to 15 versus 2 to 4 brain metastatic tumors
Adva Radiat Oncol
(2020) - et al.
Single-fraction versus multifraction (3 × 9 Gy) stereotactic radiosurgery for large (>2 cm) brain metastases: A comparative analysis of local control and risk of radiation-induced brain necrosis
Int J Radiat Oncol Biol Phys
(2016)
Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: A multicentre randomised phase 2 study
Lancet Oncol
Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): A multicentre, multicohort, open-label, phase 2 trial
Lancet Oncol
A multi-institutional prospective observational study of stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901 Study Update): Irradiation-related complications and long-term maintenance of mini-mental state examination scores
Int J Radiat Oncol Biol Phys
Brain metastasis velocity: A novel prognostic metric predictive of overall survival and freedom from whole-brain radiation therapy after distant brain failure following upfront radiosurgery alone
Int J Radiat Oncol Biol Phys
Validity of a recently proposed prognostic grading index, brain metastasis velocity, for patients with brain metastasis undergoing multiple radiosurgical procedures
Int J Radiat Oncol Biol Phys
Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: Final report of RTOG protocol 90- 05
Int J Radiat Oncol Biol Phys
Single versus multifraction stereotactic radiosurgery for large brain metastases: An international meta-analysis of 24 trials
Int J Radiat Oncol Biol Phys
Phase II trial of hypofractionated stereotactic radiotherapy for brain metastases: Results and toxicity
Radiother Oncol
Very large metastases to the brain: Retrospective study on outcomes of surgical management
World Neurosurg
Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study
Annal Oncol
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: A multicentre, open-label, single-arm, phase 1-2 trial
Lancet Oncol
Pembrolizumab for management of patients with NSCLC and brain metastases: Long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial
Lancet Oncol
Frequent use of local therapy underscores need for multidisciplinary care in the management of patients with melanoma brain metastases treated with PD-1 inhibitors
Int J Radiat Oncol Biol Phys
Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: A single-centre, randomised, controlled
phase 3 trial. Lancet Oncol
Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC.3): A multicentre, randomised, controlled, phase 3 trial
Lancet Oncol
Single-fraction stereotactic radiosurgery (SRS) Alone versus surgical resection and SRS for large brain metastases: A multi-institutional analysis
Int J Radiat Oncol Biol Phys
Whole brain irradiation following surgery or radiosurgery for solitary brain metastases: Mature results of a prematurely closed randomized Trans-Tasman Radiation Oncology Group trial (TROG 98.05)
Radiother Oncol
Hypofractionated stereotactic radiation therapy to the resection bed for intracranial metastases
Int J Radiat Oncol Biol Phys
Multidose stereotactic radiosurgery (9 Gy x 3) of the postoperative resection cavity for treatment of large brain metastases
Int J Radiat Oncol Biol Phys
Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: Phase III results of the RTOG 9508 randomised trial
Lancet
A randomized phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastases: A report of the Radiation Therapy Oncology Group (RTOG) 9104
Int J Radiat Oncol Biol Phys
Optimizing whole brain radiation therapy dose and fractionation: Results from a prospective phase 3 trial (NCCTG N107C [Alliance]/CEC.3)
Int J Radiat Oncol Biol Phys
Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): Results from a phase 3, non-inferiority, randomised trial
Lancet
Final results of the Royal College of Radiologists' trial comparing two different radiotherapy schedules in the treatment of cerebral metastases
Clin Oncol
The palliation of brain metastases: Final results of the first two studies by the Radiation Therapy Oncology Group
Int J Radiat Oncol Biol Phys
Ultra-rapid high dose irradiation schedules for the palliation of brain metastases: Final results of the first two studies by the Radiation Therapy Oncology Group
Int J Radiat Oncol Biol Phys
The palliation of brain metastases in a favorable patient population: A randomized clinical trial by the Radiation Therapy Oncology Group
Int J Radiat Oncol Biol Phys
Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials
Int J Radiat Oncol Biol Phys
Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone
Int J Radiat Oncol Biol Phys
Relationship between neurocognitive function and quality of life after whole-brain radiotherapy in patients with brain metastasis
Int J Radiat Oncol Biol Phys
A phase III, double-blind, placebo-controlled prospective randomized clinical trial of d-threo-methylphenidate HCl in brain tumor patients receiving radiation therapy
Int J Radiat Oncol Biol Phys
Randomized phase II trial of high-dose melatonin and radiation therapy for RPA class 2 patients with brain metastases (RTOG 0119)
Int J Radiat Oncol Biol Phys
Radiation dose-volume effects in the brain
Int J Radiat Oncol Biol Phys
Defining the optimal planning target volume in image-guided stereotactic radiosurgery of brain metastases: Results of a randomized trial
Int J Radiat Oncol Biol Phys
Whole brain radiotherapy versus stereotactic radiosurgery in poor-prognosis patients with one to 10 brain metastases: A randomised feasibility study
Clin Oncol
A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320
Int J Radiat Oncol Biol Phys
Dosimetric factors related to radiation necrosis after 5-fraction radiosurgery for patients with resected brain metastases
Prac Radiat Oncol
Irradiated volume as a predictor of brain radionecrosis after linear accelerator stereotactic radiosurgery
Int J Radiat Oncol Biol Phys
Adverse radiation effect after hypofractionated stereotactic radiosurgery in 5 daily fractions for surgical cavities and intact brain metastases
Int J Radiat Oncol Biol Phys
Cited by (0)
Sources of support: Guideline development was funded by the American Society for Radiation Oncology and the systematic evidence review was funded by the Patient-Centered Outcomes Research Institute.
Disclosures: All task force members’ disclosure statements were reviewed before being invited and were shared with other task force members throughout the guideline's development. Those disclosures are published within this guideline. Where potential conflicts were detected, remedial measures to address them were taken.
Paul Brown (chair): Novocure (unpaid trial leadership position), Stuart Burri: Novocure (consultant-DSMB); Vinai Gondi (vice chair): Novocure (unpaid trial leadership position), NRG Oncology (National Cancer Institute-sponsored research), Radiation Oncology Consultants (partnership), UpToDate (honoraria); Rupesh Kotecha: Accuray, Brainlab, and Elekta (honoraria, travel), AstraZeneca, Blue Earth Diagnostics, Exelixis, GT Medical Technologies, and Medtronic (all research), and Viewray (honoraria, research), Novocure (advisory board, speaker's bureau, consultant, research, travel); Jing Li: Bristol-Myers Squibb and Medtronic (research), Montaris (honoraria-ended 8/30/21); Michelle Kim: Blue Earth Diagnostics (research), International Journal of Radiation Oncology • Biology • Physics (editor); Seema Nagpal (Society for Neurological Oncology Representative): Agios, Berg Health, Inovio, and Pharmabcine (all research), Biocept (consultant, research), Novocure and Seattle Genetics (consultant), National Comprehensive Cancer Network (CNS committee); American Radium Society (CNS-AUC committee); Chad Rusthoven: Merck (research), National Comprehensive Cancer Network (CNS and SCLC committees), Takeda (research), SURVIVEit (nonprofit-board member-family member); John Suh: Neutron Therapeutics, Novocure, and Phillips (all advisory board); Wolfgang Tomé: Accuray (advisory board, consultant), Archeus (advisory board), Chrysalis (research), Varian (research, honoraria, travel), WI Alumni Research Foundation (patent/royalty); Tony Wang: Abbvie (research, travel), Cancer Panels (consultant), Doximity (stock), Elekta (consultant, honoraria), Genentech and RTOG Foundation (research), Iylon Precision Oncology (consultant), Merck (research), Novocure (advisory board, consultant), Varian (research), Wolters Kluwer (honoraria); Mateo Ziu (AANS/CNS representative): Medtronic (research). Glenn Bauman, Lisa Bradfield, Alvin Cabrera (Guideline Subcommittee representative), Lianne Kraemer, Danielle Cunningham, Bree Eaton, Jona Hattangadi-Gluth, and Alexandra Zimmer (American Society of Clinical Oncology representative) reported no disclosures.
Disclaimer and Adherence: American Society for Radiation Oncology (ASTRO) guidelines present scientific, health, and safety information and may reflect scientific or medical opinion. They are available to ASTRO members and the public for educational and informational purposes only. Commercial use of any content in this guideline without the prior written consent of ASTRO is strictly prohibited.
Adherence to this guideline does not ensure successful treatment in every situation. This guideline should not be deemed inclusive of all proper methods of care or of all factors influencing the treatment decision, nor is it intended to be exclusive of other methods reasonably directed to obtaining the same results. The physician must make the ultimate judgment regarding therapy considering all circumstances presented by the patient. ASTRO assumes no liability for the information, conclusions, and findings contained in its guidelines. This guideline cannot be assumed to apply to the use of these interventions performed in the context of clinical trials. This guideline is based on information available at the time the task force conducted its research and discussions on this topic. There may be new developments that are not reflected in this guideline and that may, over time, be a basis for ASTRO to revisit and update the guideline.
Noted—An online CME test for this article can be taken at https://academy.astro.org.